Recommended Articles
Fundraising

Arctic Therapeutics Closes Oversubscribed $21.5 Million Financing to Push New Pipeline to the Clinic

By Angeled · October 21, 2026 · Fundraising
Arctic Therapeutics Closes Oversubscribed $21.5 Million Financing to Push New Pipeline to the Clinic
Arctic Therapeutics Closes Oversubscribed $21.5 Million Financing to Push New Pipeline to the Clinic

The news

Arctic Therapeutics, a clinical-stage biopharmaceutical company based in Reykjavik and Philadelphia, has closed an oversubscribed US$21.5 million late-stage venture round, announced on October 21, 2026. The financing was increased following strong investor demand. The round was led by investment firm Pekron, Investcorp-backed Sanos Group, Icelandic investment company Kaldbakur and Landvættir, a venture fund managed by AxUM Securities.

Proceeds will primarily advance two pipeline assets — AT-002 and AT-003 — toward clinical development, broadening the company beyond its lead programs.

Background and context

Arctic Therapeutics describes a genomics-driven drug discovery approach: it identifies disease biology through human genetics and translates those findings into treatments. This strategy has a particular pedigree in Iceland, whose unusually homogeneous population and rich genetic records have long made the country a natural laboratory for linking genes to disease.

The company's pipeline spans several areas of unmet medical need:

  • AT-001 — targeting rare and common forms of dementia; has reached key Phase II milestones.
  • AT-004 — for inflammatory skin diseases; also at key Phase II milestones.
  • AT-002 — targeting autoimmune uveitis, an inflammatory eye condition, with potential applications across lupus and psoriasis.
  • AT-003 — addressing CLEC16A, a gene linked to 16 autoimmune diseases including multiple sclerosis and type 1 diabetes.

The new financing follows an oversubscribed Series A of roughly US$31 million that funded the lead programs through their Phase II milestones, and it comes after the company's participation in acquiring the lead asset of US-based Nobias Therapeutics and the launch of Synaptiq Therapeutics — signals that Arctic is consolidating and expanding its asset base in parallel.

"Our Series A enabled us to move our lead programs forward and achieve the clinical milestones we set out to reach," said co-founder and chief executive officer Ivar Hakonarson. He said the new money lets the company "unlock additional value within the broader pipeline" while advancing partnering and out-licensing efforts for AT-001 and AT-004.

What it means / key details

  • Round size: US$21.5 million, oversubscribed and upsized on demand.
  • Lead backers: Pekron, Sanos Group (Investcorp-backed), Kaldbakur and Landvættir (managed by AxUM Securities).
  • Use of proceeds: advance AT-002 and AT-003 toward clinical development; support partnering and out-licensing for AT-001 and AT-004.
  • Prior round: oversubscribed Series A of ~US$31 million funded lead programs to Phase II milestones.
  • Pipeline logic: human-genetics-driven discovery; AT-003's CLEC16A target touches 16 autoimmune indications, a classic "one gene, many diseases" platform play.

Why it matters for founders

Arctic's trajectory illustrates a disciplined biotech playbook. Rather than rushing everything into the clinic at once, the company used its Series A to de-risk the two lead assets to Phase II milestones, then raised a fresh round — on stronger terms, evidenced by the oversubscription — to expand the pipeline. For biotech founders, the lesson is that clinical milestones are the currency of credibility: each data point earned makes the next raise easier and less dilutive. The parallel moves — acquiring Nobias's lead asset, launching Synaptiq Therapeutics, pursuing out-licensing for mature programs — also show how small biotechs can operate like asset managers, monetizing de-risked programs while redeploying capital into earlier, higher-upside biology.

Why it matters for investors

Oversubscribed follow-on rounds are a strong signal in biotech: they indicate that existing investors saw enough clinical progress to double down and that new investors were willing to compete for allocation. At $21.5 million, the round is modest by US biotech standards but substantial for an Icelandic clinical-stage company — and the geographic mix of backers (Icelandic institutions alongside Investcorp-linked capital) suggests the company is broadening its investor base beyond its home market. The key value driver ahead is clinical: AT-002 and AT-003 moving toward first trials, plus any partnering deals for the Phase II-stage AT-001 and AT-004. Investors in rare-disease and autoimmune assets should watch how the out-licensing process prices two de-risked programs — that outcome will set the valuation reference for everything downstream.

Angeled.com connects founders with investors.

Source: dealroom.co

Read Next